EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudie

Stereotactic Versus Standard Tumor Irradiation in Unresectable Locally Advanced Non-small Cell Lung Cancer With Durvalumab Maintenance: A Multicenter Study With Propensity Score Matching

Etienne Cedoz, Antonin Levy, Isabelle Martel-Lafay, Pierre-Yves Bondiau, Cécile Le Péchoux, Christos Chouaid, Arnaud Colomb, Victoria Ferrari, Myriam Ayadi, Jérôme Doyen, Benoît Allignet

International Journal of Radiation Oncology*Biology*Physics · 2026

DOI: 10.1016/j.ijrobp.2025.10.005 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026. Verfasst von Etienne Cedoz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Centre Léon Bérard, Lyon, France. Electronic address: etienne.cedoz@lyon.unicancer.fr. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Radiosurgery, Antibodies, Monoclonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Tumor control in locally advanced non-small cell lung cancer (LA-NSCLC) is associated with patient prognosis, sustaining ongoing research in dose-escalation strategies. This study evaluates the efficacy and safety of tumor stereotactic body radiation therapy (T-SBRT) compared with tumoral normofractionated chemoradiation therapy followed by immunotherapy. METHODS AND MATERIALS: This retrospective multicenter study included patients with unresectable LA-NSCLC treated between July 2017 and January 2023. Eligible patients received ≥60 Gy normofractionated radiation therapy, ≥1 cycle of chemotherapy, and ≥1 cycle of durvalumab. The T-SBRT group received mediastinal normofractionated radiation therapy and ultrahypofractionated primary tumor irradiation. Propensity score matching (PSM) was performed to limit confounding effects. RESULTS: Among the 208 included patients, 21 (10%) received T-SBRT. Median age was 64.0 years, and most had adenocarcinoma (59.1%). There were no differences in patients' characteristics except stages and T stages (not observed in T stage after PSM). The most frequent SBRT regimen was 50 Gy in 5 fractions (28.6%). After a median follow-up of 38 months (95% CI, 26.0-57.0), T-SBRT was associated with longer progression-free survival in overall cohort (median not reached vs 22.8 months; hazard ratio [HR] = 0.46; 95% CI 0.21-0.99; P = .046), and after PSM (HR = 0.41; 95% CI, 0.18-0.92; P = .031). T-SBRT also tended to be associated with longer overall survival in both overall and PSM cohorts (HR = 0.54, 95% CI 0.22-1.33, P = .18; HR = 0.46, 95% CI, 0.18-1.18, P = .11, respectively). Acute grade 3 toxicities were comparable, without grade 4-5 events. However, given the limited number of patients, these results should be interpreted with caution and considered exploratory. CONCLUSIONS: T-SBRT in LA-NSCLC is significantly associated with longer progression-free survival with a trend toward prolonged overall survival, without increasing toxicity. Further studies are needed to refine optimal timing and immunologic synergy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsRadiosurgeryAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalHumansMaleMiddle AgedFemalePropensity ScoreRetrospective StudiesAgedChemoradiotherapyAged, 80 and overProgression-Free Survival

Substanzen

durvalumabAntibodies, MonoclonalAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Radiation Oncology, Centre Léon Bérard, Lyon, France. Electronic address: etienne.cedoz@lyon.unicancer.fr.
  • Department of Radiation Oncology, Gustave Roussy, Villejuif, France; Gustave Roussy, Inserm U1030, Université Paris-Saclay, Villejuif, France; Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
  • Department of Radiation Oncology, Centre Léon Bérard, Lyon, France.
  • Department of Radiation Oncology, Centre Antoine Lacassagne, Nice, France.
  • Department of Radiation Oncology, Gustave Roussy, Villejuif, France.
  • Department of Pneumology, Centre Hospitalier Intercommunal de Créteil, Créteil, France.

Zitieren

APA

Cedoz, E., Levy, A., Martel-Lafay, I., Bondiau, P. Y., Le Péchoux, C., Chouaid, C., Colomb, A., Ferrari, V., Ayadi, M., Doyen, J., & Allignet, B. (2026). Stereotactic Versus Standard Tumor Irradiation in Unresectable Locally Advanced Non-small Cell Lung Cancer With Durvalumab Maintenance: A Multicenter Study With Propensity Score Matching. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2025.10.005

Vancouver

Cedoz E, Levy A, Martel-Lafay I, Bondiau PY, Le Péchoux C, Chouaid C, et al. Stereotactic Versus Standard Tumor Irradiation in Unresectable Locally Advanced Non-small Cell Lung Cancer With Durvalumab Maintenance: A Multicenter Study With Propensity Score Matching. International Journal of Radiation Oncology*Biology*Physics. 2026. doi:10.1016/j.ijrobp.2025.10.005

BibTeX
@article{Cedoz2026,
  author = {Cedoz, Etienne and Levy, Antonin and Martel-Lafay, Isabelle and Bondiau, Pierre-Yves and Le Péchoux, Cécile and Chouaid, Christos and Colomb, Arnaud and Ferrari, Victoria and Ayadi, Myriam and Doyen, Jérôme and Allignet, Benoît},
  title = {Stereotactic Versus Standard Tumor Irradiation in Unresectable Locally Advanced Non-small Cell Lung Cancer With Durvalumab Maintenance: A Multicenter Study With Propensity Score Matching},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2026},
  doi = {10.1016/j.ijrobp.2025.10.005}
}
Kostenlos starten →